Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Galecto Inc (GLTO)

Galecto Inc (GLTO)
2.68 +0.26 (+10.74%) 04/22/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 2.50 -0.18 (-6.72%) 17:05 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.50
Day High
2.80
Open 2.59
Previous Close 2.42 2.42
Volume 87,267 87,267
Avg Vol 79,913 79,913
Stochastic %K 36.42% 36.42%
Weighted Alpha -77.42 -77.42
5-Day Change +0.19 (+7.63%) +0.19 (+7.63%)
52-Week Range 2.01 - 18.50 2.01 - 18.50
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,200
  • Shares Outstanding, K 1,322
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,440 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -5.00
  • Growth Rate Est. (year over year) +20,080.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.01 +33.33%
on 04/09/25
Period Open: 6.10
7.10 -62.25%
on 03/24/25
-3.42 (-56.07%)
since 03/21/25
3-Month
2.01 +33.33%
on 04/09/25
Period Open: 5.50
7.30 -63.29%
on 03/21/25
-2.82 (-51.27%)
since 01/22/25
52-Week
2.01 +33.33%
on 04/09/25
Period Open: 17.02
18.50 -85.51%
on 05/03/24
-14.34 (-84.26%)
since 04/22/24

Most Recent Stories

More News
Galecto Reports Full-Year 2024 Financial Results

GLTO : 2.68 (+10.74%)
Galecto to Participate in Upcoming Investor Conferences

GLTO : 2.68 (+10.74%)
Galecto Reports Third Quarter 2024 Financial Results

GLTO : 2.68 (+10.74%)
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

GLTO : 2.68 (+10.74%)
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

GLTO : 2.68 (+10.74%)
Nasdaq Futures Climb as Bond Yields Retreat From Decade Highs, Micron Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ23) are trending up +0.44% this morning as U.S. Treasury yields slipped from decade highs, while investors braced for a new round of economic data as well as an earnings...

DKNG : 33.47 (+3.18%)
GOOGL : 151.47 (+2.57%)
GLTO : 2.68 (+10.74%)
AAPL : 199.74 (+3.41%)
HMB.S.DX : 142.100 (+1.79%)
ZION : 43.13 (-1.12%)
MU : 70.21 (+5.20%)
NQZ23 : 16,530.23s (-0.07%)
JEF : 43.40 (+4.38%)
CRDF : 3.05 (+8.16%)
COST : 979.23 (+2.24%)
PAYX : 143.29 (+2.07%)
Galecto Reports Second Quarter Operating and Financial Results

BOSTON, July 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...

GLTO : 2.68 (+10.74%)
Galecto to Participate at Jefferies Healthcare Conference

BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...

GLTO : 2.68 (+10.74%)
Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified Galecto’s oral galectin-3 inhibitor candidate, GB1211, reverses...

GLTO : 2.68 (+10.74%)
Galecto Reports First Quarter Operating and Financial Results

BOSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...

GLTO : 2.68 (+10.74%)
Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor GALACTIC-1 trial on track to deliver top-line results in mid-2023...

GLTO : 2.68 (+10.74%)
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022 Part 1 of GULLIVER-2 trial completed with positive results as previously...

GLTO : 2.68 (+10.74%)
Galecto Reports Financial Results for the Year Ended December 31, 2021

Continued pipeline progress with three potentially first-in-class product candidates Strong cash position with cash runway into 2H 2024 BOSTON, Feb. 17,...

GLTO : 2.68 (+10.74%)
Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease Company Provides...

GLTO : 2.68 (+10.74%)
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients Galecto...

GLTO : 2.68 (+10.74%)
Galecto Reports Third Quarter Operating and Financial Results

Announces clinical collaboration with Roche for first line NSCLC Remains on track with clinical data milestone timing BOSTON, Nov. 04, 2021 (GLOBE...

GLTO : 2.68 (+10.74%)
Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Upcoming Phase 2 trial marks expansion of Galecto pipeline into oncology and provides opportunity for exploring the use of galectin-3 inhibitors in cancer ...

GLTO : 2.68 (+10.74%)
Galecto to Present at Upcoming Investor Conferences

BOSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...

GLTO : 2.68 (+10.74%)
Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...

GLTO : 2.68 (+10.74%)
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications

GLTO : 2.68 (+10.74%)

Business Summary

Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters...

See More

Key Turning Points

3rd Resistance Point 3.12
2nd Resistance Point 2.96
1st Resistance Point 2.82
Last Price 2.68
1st Support Level 2.52
2nd Support Level 2.36
3rd Support Level 2.22

See More

52-Week High 18.50
Fibonacci 61.8% 12.20
Fibonacci 50% 10.26
Fibonacci 38.2% 8.31
Last Price 2.68
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro